Back To: Home

CLICK HERE FOR WHAT'S NEW IN:
 




 

PhaseBio’s PB1046 reduces fibrosis in DMD models
June 2015
SHARING OPTIONS:

MALVERN, Pa.—PhaseBio Pharmaceuticals Inc. recently presented positive preclinical data on its compound PB1046 in Duchenne muscular dystrophy (DMD) models at the 67th American Academy of Neurology Annual Meeting. The data came from a study conducted by QTest Labs in collaboration with Nationwide Children’s Hospital and the Ohio State College of Veterinary Medicine. In dystrophin-deficient (MDX) mice, chronic treatment with PB1046 alleviated DMD myopathies, slowed cardiac deterioration and protected skeletal muscle by reducing fibrosis. In-vivo analysis found that PB1046 treatment caused improved cardiac contractility and relaxation and also significantly decreased gastrocnemius collagen content, an indicator of fibrosis, as well as collagen content in MDX heart muscle.
 
“Results of this preclinical study support the continued advancement of PB1046 into clinical trials for cardiomyopathy in DMD and BMD patients,” said PhaseBio CEO Jonathan Mow. “Moreover, this novel approach might serve as a complementary therapy to other DMD compounds in clinical development.”

Back



PAGE UTILITIES


CONTACT US
DDNEWS
Published by Old River Publications LLC
19035 Old Detroit Road
Rocky River, OH USA 44116
Ph: 440-331-6600  |  Fax: 440-331-7563
 
© Copyright 2017 Old River Publications LLC. All righs reserved.  |  Web site managed and designed by OffWhite.